Company Endoclyn Srl with Fiscal Code 14624330
recorded a turnover of 2024 of
84.772,
with a net profit of
38.574
and having an average number of employees of
2.
The company operates in the field of Activităţi de asistenţă medicală specializată having the NACE code 8622.
Sales - Ron
Sales, Profit, Employees, Total Income, Financial Results -
Endoclyn Srl
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Sales - EUR
37.207
41.755
45.888
44.729
46.784
64.114
72.285
76.997
80.841
84.772
Total Income - EUR
37.214
41.755
45.900
44.737
46.792
65.054
76.849
77.029
80.881
84.819
Total Expenses - EUR
19.146
19.311
18.503
27.706
27.379
31.516
30.681
32.951
33.388
43.752
Gross Profit/Loss - EUR
18.068
22.444
27.397
17.031
19.414
33.537
46.168
44.078
47.493
41.067
Net Profit/Loss - EUR
16.952
22.027
26.938
16.584
18.946
32.887
45.471
43.323
46.700
38.574
Employees
0
3
6
2
3
3
2
2
2
2
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales increased by 5.5%, from 80.841 euro in the year 2023, to 84.772 euro in 2024.
The Net Profit decreased by -7.866 euro, from 46.700 euro in 2023, to 38.574 in the last year.
Check the financial reports for the company - Endoclyn Srl
Financial Rating - ENDOCLYN SRL
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - Endoclyn Srl
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - Endoclyn Srl
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - Endoclyn Srl
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
56.095 euro in 2024 which includes Inventories of
0 euro, Receivables of
94 euro and cash availability of
56.001 euro.
The company's Equity was valued at
43.069 euro, while total Liabilities amounted to
16.692 euro.
Equity decreased by -7.866 euro, from 51.220 euro in 2023, to 43.069 in 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Endoclyn Srl